These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9472201)

  • 1. Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events.
    Stewart WC; Garrison PM
    Arch Intern Med; 1998 Feb; 158(3):221-6. PubMed ID: 9472201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
    Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
    Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
    Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma.
    Ergin A; Ornek K; Güllü R; Bulcun E; Ekici M; Ekici A
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):463-6. PubMed ID: 19552600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
    Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J
    Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of dorzolamide–timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study.
    Crichton AC; Harasymowycz P; Hutnik CM; Behki R; Boucher S; Ibrahim F; Rifkind AW; Solomon L; Liao C; Bastien NR; Sampalis JS
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):503-11. PubMed ID: 20874498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selectivity of site of action and systemic effects of topical alpha agonists.
    Robin AL; Burnstein Y
    Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans.
    Kaufman PF
    Arch Ophthalmol; 1999 May; 117(5):673-4. PubMed ID: 10326968
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
    Maus TL; Nau C; Brubaker RF
    Arch Ophthalmol; 1999 May; 117(5):586-91. PubMed ID: 10326954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma.
    Tamada Y; Taniguchi T; Murase H; Yamamoto T; Kitazawa Y
    J Ocul Pharmacol Ther; 2001 Feb; 17(1):19-25. PubMed ID: 11322634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
    Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
    Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
    Konstas AG; Karabatsas CH; Lallos N; Georgiadis N; Kotsimpou A; Stewart JA; Stewart WC
    Ophthalmology; 2005 Apr; 112(4):603-8. PubMed ID: 15808251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative analysis of the effects of the fixed combination of timolol and dorzolamide versus latanoprost plus timolol on ocular hemodynamics and visual function in patients with primary open-angle glaucoma.
    Siesky B; Harris A; Sines D; Rechtman E; Malinovsky VE; McCranor L; Yung CW; Zalish M
    J Ocul Pharmacol Ther; 2006 Oct; 22(5):353-61. PubMed ID: 17076630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dorzolamide/timolol and latanoprost/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma.
    Eren MH; Gungel H; Altan C; Pasaoglu IB; Sabanci S
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):381-6. PubMed ID: 22320418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.